12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)

This study was conducted to assess the efficacy, safety, and immunogenicity of canakinumab administered as a subcutaneous injection to patients with CAPS. Herein we report the results of 5 children (4–13 years) and 2 adolescents (16 and 17 years) enrolled in the study. All had documented NALP-3 gene mutations. Entry criteria were active disease evaluated by moderate to severe symptoms of CAPS (based on a 5 point global physician's assessment...